Browse Studies — Arctuva

Phase 2

MC230716 Pilot Single-Arm, Pragmatic Trial Of In-Home Versus In-Clinic Subcutaneous Nivolumab Administration Through Cancer CARE (Connected Access And Remote Expertise) Beyond Walls (CCBW) Program

This phase II trial compares the impact of subcutaneous (SC) nivolumab given in an in-home setting to an in-clinic setting on cancer care and quality of life. …

Advanced Esophageal Squamous Cell CarcinomaAdvanced Renal Cell CarcinomaClinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8+28 more

Estimated

~$10 – $6,250

Mayo ClinicNCT06265285

Phase 1

PNV21-001: A Phase I Study of a Personalized Multi-Peptide Neo-Antigen Vaccine in Breast Cancer, Pre-Treated Nonsmall Cell Lung Cancer and PD1/PD-L1 Inhibitor-Refractory Melanoma

This phase I trial studies the safety of personalized neo-antigen peptide vaccine in treating patients with stage IIIC-IV melanoma, hormone receptor positive H…

Anatomic Stage IV Breast Cancer AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Locally Advanced Cutaneous Melanoma+22 more

Estimated

Phase 1

A Phase II Trial of MOR Antagonism With Axelopran and Nivolumab in PD-1-Refractory Metastatic Melanoma (MORALE-MM)

This first-in-human study will evaluate the safety, clinical activity, and immunologic effects of combining axelopran with nivolumab in patients with PD-1-refr…

Unresectable Cutaneous Melanoma

Estimated

~$10 – $7,500

John KirkwoodNCT07631325

Phase 2

The TIME Trial - Phase II Randomized Controlled Trial of Time-of-Day Specified Immunotherapy for Advanced Melanoma

This phase II trial tests the safety and effectiveness of giving ipilimumab and nivolumab in the morning compared to other times of day in treating patients wi…

Advanced Acral MelanomaAdvanced Cutaneous MelanomaAdvanced Mucosal Melanoma+7 more

Estimated

~$10 – $6,250

Emory UniversityNCT07155317